REG - Oxford Cannabinoid - Registered Office Address Change

Oxford Cannabinoid Technologies HoldingsAnnouncement

01/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220401:nRSA8594Ga&default-theme=true

RNS Number : 8594G  Oxford Cannabinoid Tech.Holdings  01 April 2022

 

 

Oxford Cannabinoid Technologies Holdings plc

("OCTP" or the "Company")

Registered Office Address Change

 

Oxford Cannabinoid Technologies Holdings plc announces that it has changed its
registered office to Prama House, 267 Banbury Road, Oxford OX2 7HT with effect
from yesterday, 31 March 2022.

Enquiries:

 Oxford Cannabinoid Technologies Holdings plc  +44 (0)20 3034 2820

 Dr John Lucas (CEO)                           john@oxcantech.com (mailto:john@oxcantech.com)

 Clarissa Sowemimo-Coker (COO)                 clarissa@oxcantech.com

 Cairn Financial Advisers

 Emily Staples                                 +44 (0)20 7213 0897

 Jo Turner                                     +44 (0) 20 7213 0885

 Walbrook PR Limited                           +44 (0)20 7933 8780

 Paul Vann                                     +44 (0)7768 807631

 Nicholas Johnson                              oxcantech@walbrookpr.com

 Harbor Access LLC

 Jonathan Paterson                             +1 (203) 862 0492

 Richard Leighton                              Richard.Leighton@harboraccessllc.com

 

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc is the holding company of Oxford
Cannabinoid Technologies Ltd, a pharmaceutical company developing prescription
cannabinoid medicines for approval by key medicines regulatory agencies
worldwide and targeting the U$ multi-billion pain market (together the
"Group"). Cannabinoids are compounds found in the cannabis plant that have
been shown to have a range of therapeutic effects on the body, including pain
relief. The Group has a clearly defined path to commercialisation, revenues
and growth. The Group is developing drug candidates through clinical trials to
gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals
to prescribe them with confidence.

The Group's portfolio aims to balance risk, value and time to market, whilst
ensuring market exclusivity around all its key activities. The Group's lead
compound, OCT461201, is a highly potent and selective CB2 agonist and is being
developed by OCT in a solid oral dosage form. OCT is conducting pre-clinical
testing and development with pre-clinical trials scheduled for 2022. The
Group's product pipeline also uses a balanced drug product strategy that
employs both natural and synthetic compounds for the treatment of rare
diseases and includes chemically modified phytocannabinoids with improved
drug-like characteristics and a proprietary library of cannabinoids.

OCTP operates a partnership model with external academic and commercial
partners.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CROBKDBKFBKDQNN